PET radiotracers for molecular imaging in the brain: Past, present and future

NeuroImage

Volumn 61, Issue 2, 2012, Pages 363-370

  Zimmer, Luc ^a,b   Luxen, André ^c  

^a UNIVERSITÉ DE LYON   (France)

^b CERMEP IMAGERIE DU VIVANT   (France)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Biomarker; Brain; Drug discovery; Neurology; PET; Psychiatry; Radiopharmaceuticals

Indexed keywords

3' FLUOROTHYMIDINE F 18; 6 FLUORODOPA F 18; CARBON 11; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; G PROTEIN COUPLED RECEPTOR; GLYCOPROTEIN P; IODINE 123; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; RACLOPRIDE C 11; TRACER;

ALZHEIMER DISEASE; BINDING AFFINITY; BRAIN METABOLISM; BRAIN TUMOR; EPILEPSY; FUNCTIONAL NEUROIMAGING; GLUCOSE METABOLISM; HUMAN; INTERNALIZATION; MOLECULAR IMAGING; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BRAIN; BRAIN CHEMISTRY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INFLAMMATION; NERVOUS SYSTEM NEOPLASMS; NEURODEGENERATIVE DISEASES; NUCLEAR MEDICINE; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RADIOPHARMACEUTICALS;

EID: 84860750674     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2011.12.037     Document Type: Review

References (103)

1. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int. J. Neuropsychopharmacol. Suppl. 2004, 1:S1-S5.
2. Ametamey S.M., Honer M., Schubiger P.A. Molecular imaging with PET. Chem. Rev. 2008, 108:1501-1516.
3. Aznavour N., Zimmer L. [18F]MPPF as a tool for the in vivo imaging of 5-HT1A receptors in animal and human brain. Neuropharmacology 2007, 52:695-707.
4. Aznavour N., Rbah L., Riad M., Reilhac A., Costes N., Descarries L., Zimmer L. A PET imaging study of 5-HT(1A) receptors in cat brain after acute and chronic fluoxetine treatment. NeuroImage 2006, 33:834-842.
5. Barros L.F., Porras O.H., Bittner C.X. Why glucose transport in the brain matters for PET. Trends Neurosci. 2005, 28:117-119.
6. Bernard V., Décossas M., Liste I., Bloch B. Intraneuronal trafficking of G-protein-coupled receptors in vivo. Trends Neurosci. 2006, 29:140-147.
7. Borbely K., Wintermark M., Martos J., Fedorcsak I., Bognar L., Kasler M. The pre-requisite of a second-generation glioma PET biomarker. J. Neurol. Sci. 2010, 298:11-16.
8. Boss A., Bisdas S., Kolb A., Hofmann M., Ernemann U., Claussen C.D., Pfannenberg C., Pichler B.J., Reimold M., Stegger L. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J. Nucl. Med. 2010, 51:1198-1205.
9. Bjorklund L.M., Sánchez-Pernaute R., Chung S., Andersson T., Chen I.Y., McNaught K.S., Brownell A.L., Jenkins B.G., Wahlestedt C., Kim K.S., Isacson O. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:2344-2349.
10. Brooks D.J. PET studies on the function of dopamine in health and Parkinson's disease. Ann. N. Y. Acad. Sci. 2003, 991:22-35.
11. Brooks D.J. Dopaminergic action beyond its effects on motor function: imaging studies. J. Neurol. 2006, 253(Suppl. 4):8-15.
12. Brownell A.L., Jenkins B.G., Elmaleh D.R., Deacon T.W., Spealman R.D., Isacson O. Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease. Nat. Med. 1998, 4:1308-1312.
13. Cai L., Lu S., Pike V.W. Chemistry with [18F]fluoride ion. Eur. J. Org. Chem. 2008, 2853-2873.
14. Catana C., Wu Y., Judenhofer M.S., Qi J., Pichler B.J., Cherry S.R. Simultaneous acquisition of multislice PET and MR images: initial results with a MR-compatible PET scanner. J. Nucl. Med. 2006, 47:1968-1976.
15. Chauveau F., Boutin H., Van Camp N., Dollé F., Tavitian B. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:2304-2319.
16. Cross S., Cruciani G. Molecular fields in drug discovery: getting old or reaching maturity?. Drug Discov. Today 2010, 15:23-32.
17. Cumming P., Wong D.F., Dannals R.F., Gillings N., Hilton J., Scheffel U., Gjedde A. The competition between endogenous dopamine and radioligands for specific binding to dopamine receptors. Ann. N. Y. Acad. Sci. 2002, 965:440-450.
18. Cumming P., Gillings N.M., Jensen S.B., Bjarkam C., Gjedde A. Kinetics of the uptake and distribution of the dopamine D(2,3) agonist (R)-N-[1-(11)C]n-propylnorapomorphine in brain of healthy and MPTP-treated Göttingen miniature pigs. Nucl. Med. Biol. 2003, 30:547-553.
19. De Leon-Rodriguez L.M., Lubag A.J.M., Malloy C.R., Martinez G.V., Gillies R.J., Sherry A.D. Responsive MRI agents for sensing metabolism in vivo. Acc. Chem. Res. 2009, 42:948-957.
20. Derry C., Benjamin C., Bladin P., Le Bars D., Tochon-Danguy H., Berkovic S.F., Zimmer L., Costes N., Mulligan R., Reutens D. Increased serotonin receptor availability in human sleep: evidence from an [18F]MPPF PET study in narcolepsy. NeuroImage 2005, 30:341-348.
21. Egerton A., Shotbolt J.P., Stokes P.R., Hirani E., Ahmad R., Lappin J.M., Reeves S.J., Mehta M.A., Howes O.D., Grasby P.M. Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: an [11C]raclopride PET study. NeuroImage 2010, 50:260-266.
22. Elsinga P.H., Hatano K., Ishiwata K. PET tracers for imaging of the dopaminergic system. Curr. Med. Chem. 2006, 13:2139-2153.
23. Emerit M.B., el Mestikawy S., Gozlan H., Rouot B., Hamon M. Physical evidence of the coupling of solubilized 5-HT1A binding sites with G regulatory proteins. Biochem. Pharmacol. 1990, 39:7-18.
24. Emond P., Guilloteau D., Chalon S. PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter. CNS Neurosci. Ther. 2008, 14:47-64.
25. Ewers M., Sperling R.A., Klunk W.E., Weiner M.W., Hampel H. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci. 2011, 34:430-442.
26. Finnema S.J., Bang-Andersen B., Wikström H.V., Halldin C. Current state of agonist radioligands for imaging of brain dopamine D2/D3 receptors in vivo with positron emission tomography. Curr. Top. Med. Chem. 2010, 10:1477-1498.
27. Fodero-Tavoletti M.T., Okamura N., Furumoto S., Mulligan R.S., Connor A.R., McLean C.A., Cao D., Rigopoulos A., Cartwright G.A., O'Keefe G., Gong S., Adlard P.A., Barnham K.J., Rowe C.C., Masters C.L., Kudo Y., Cappai R., Yanai K., Villemagne V.L. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain 2011, 134:1089-1100.
28. Fowler J.S., Wolf A.P. Working against time: rapid radiotracer synthesis and imaging the human brain. Acc. Chem. Res. 1997, 30:181-188.
29. Fromm M.F. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. 2004, 25:423-429.
30. Ginovart N. Imaging the dopamine system with in vivo [11C]raclopride displacement studies: understanding the true mechanism. Mol. Imaging Biol. 2005, 7:45-52.
31. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
32. Graeber M.B., Li W., Rodriguez M.L. Role of microglia in CNS inflammation. FEBS Lett. 2011, 585:3798-3805.
33. Graff-Guerrero A., Willeit M., Ginovart N., Mamo D., Mizrahi R., Rusjan P., Vitcu I., Seeman P., Wilson A.A., Kapur S. Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. Hum. Brain Mapp. 2008, 29:400-410.
34. Heiss W.D., Herholz K. Brain receptor imaging. J. Nucl. Med. 2006, 47:302-312.
35. Herholz K. Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease. Expert. Rev. Neurother. 2010, 10:1667-1673.
36. Herholz K., Ebmeier K. Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol. 2011, 10:667-670.
37. Hustinx R., Fosse P. PET in brain tumors. PET Clin. 2010, 5:185-197.
38. Ikoma Y., Takano A., Ito H., Kusuhara H., Sugiyama Y., Arakawa R., Fukumura T., Nakao R., Suzuki K., Suhara T. Quantitative analysis of 11C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function. J. Nucl. Med. 2006, 47:1531-1537.
39. Jaffer F.A., Weissleder R. Molecular imaging in the clinical arena. JAMA 2005, 293:855-862.
40. Judenhofer M.S., Catana C., Swann B.K., Siegel S.B., Jung W.I., Nutt R.E., Cherry S.R., Claussen C.D., Pichler B.J. PET/MR images acquired with a compact MR-compatible PET detector in a 7-T magnet. Radiology 2007, 244:807-814.
41. Judenhofer M.S., Wehrl H.F., Newport D.F., Catana C., Siegel S.B., Becker M., Thielscher A., Kneilling M., Lichy M.P., Eichner M., Klingel K., Reischl G., Widmaier S., Röcken M., Nutt R.E., Machulla H.J., Uludag K., Cherry S.R., Claussen C.D., Pichler B.J. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat. Med. 2008, 14:459-465.
42. Kadir A., Nordberg A. Target-specific PET probes for neurodegenerative disorders related to dementia. J. Nucl. Med. 2010, 51:1418-1430.
43. Kannan P., John C., Zoghbi S.S., Halldin C., Gottesman M.M., Innis R.B., Hall M.D. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin. Pharmacol. Ther. 2009, 86:368-377.
44. Kegeles L.S., Mann J.J. In vivo imaging of neurotransmitter systems using radiolabeled receptor ligands. Neuropsychopharmacology 1997, 17:293-307.
45. Kikuchi A., Takeda A., Okamura N., Tashiro M., Hasegawa T., Furumoto S., Kobayashi M., Sugeno N., Baba T., Miki Y., Mori F., Wakabayashi K., Funaki Y., Iwata R., Takahashi S., Fukuda H., Arai H., Kudo Y., Yanai K., Itoyama Y. In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain 2010, 133:1772-1778.
46. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergström M., Savitcheva I., Huang G.F., Estrada S., Ausén B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Långström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
47. Kobilka B. Adrenergic receptors as models for G protein-coupled receptors. Annu. Rev. Neurosci. 1992, 15:87-114.
48. Kortekaas R., Maguire R.P., Cremers T.I., Dijkstra D., van Waarde A., Leenders K.L. In vivo binding behavior of dopamine receptor agonist (+)-PD 128907 and implications for the "ceiling effect" in endogenous competition studies with [(11)C]raclopride-a positron emission tomography study in Macaca mulatta. J. Cereb. Blood Flow Metab. 2004, 24:531-535.
49. Kreisl W.C., Liow J.S., Kimura N., Seneca N., Zoghbi S.S., Morse C.L., Herscovitch P., Pike V.W., Innis R.B. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. J. Nucl. Med. 2010, 51:559-566.
50. Kumar J.S., Prabhakaran J., Majo V.J., Milak M.S., Hsiung S.C., Tamir H., Simpson N.R., Van Heertum R.L., Mann J.J., Parsey R.V. Synthesis and in vivo evaluation of a novel 5-HT1A receptor agonist radioligand [O-methyl-11C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione in nonhuman primates. Eur. J. Nucl. Med. Mol. Imaging 2007, 34:1050-1060.
51. Lam V.W., No D.C., Wong W.Y., Ong S.C., Yu S.W., See S.J. Promising role of [18F] fluorocholine PET/CT vs [18F] fluorodeoxyglucose PET/CT in primary brain tumors-early experience. Clin. Neurol. Neurosurg. 2011, 113:156-161.
52. Lancelot S., Zimmer L. Small-animal positron emission tomography as a tool for neuropharmacology. Trends Pharmacol. Sci. 2010, 31:411-417.
53. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab. 2000, 20:423-451.
54. Lazarova N., Zoghbi S.S., Hong J., Seneca N., Tuan E., Gladding R.L., Liow J.S., Taku A., Innis R.B., Pike V.W. Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. J. Med. Chem. 2008, 51:6034-6043.
55. Lee G., Bendayan R. Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders. Pharm. Res. 2004, 21:1313-1330.
56. Lemoine L., Verdurand M., Vacher B., Blanc E., Le Bars D., Newman-Tancredi A., Zimmer L. [18F]F15599, a novel 5-HT1A receptor agonist, as a radioligand for PET neuroimaging. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:594-605.
57. Ma Y., Tang C., Chaly T., Greene P., Breeze R., Fahn S., Freed C., Dhawan V., Eidelberg D. Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes. J. Nucl. Med. 2010, 51:7-15.
58. Man S., Ubogu E.E., Ransohoff R.M. Inflammatory cell migration into the central nervous system: a few new twists on an old tale. Brain Pathol. 2007, 17:243-250.
59. Miller P.W., Long N.J., Vilar R., Gee A.D. Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography. Angew. Chem. Int. Ed. 2008, 47:8998-9033.
60. Mongeau R., Welner S.A., Quirion R., Suranyi-Cadotte B.E. Further evidence for differential affinity states of the serotonin 1A receptor in rat hippocampus. Brain Res. 1992, 590:229-238.
61. Narendez R., Martinez D. Cocaine abuse and sensitization of striatal dopamine transmission: a critical review of the preclinical and clinical imaging literature. Synapse 2008, 62:851-869.
62. Nénonéné E.K., Radja F., Carli M., Grondin L., Reader T.A. Heterogeneity of cortical and hippocampal 5-HT1A receptors: a reappraisal of homogenate binding with 8-[3H]hydroxydipropylaminotetralin. J. Neurochem. 1994, 62:1822-1834.
63. Newmann-Tancredi A. Biased agonism at serotonin 5-HT1A receptors: preferential postsynaptic activity for improved therapy of CNS disorders. Neuropsychiatry 2011, 1:149-164.
64. Paterson L.M., Tyacke R.J., Nutt D.J., Knudsen G.M. Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. J. Cereb. Blood Flow Metab. 2010, 30:1682-1706.
65. Pellerin L., Bouzier-Sore A.K., Aubert A., Serres S., Merle M., Costalat R., Magistretti P.J. Activity-dependent regulation of energy metabolism by astrocytes: an update. Glia 2007, 55:1251-1262.
66. Petrirena G.J., Goldman S., Delattre J.Y. Advances in PET imaging of brain tumors: a referring physician's perspective. Curr. Opin. Oncol. 2011, 23:617-623.
67. Phelps M.E. Positron emission tomography provides molecular imaging of biological processes. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:9226-9233.
68. Phelps M.E., Mazziotta J.C. Positron emission tomography: human brain function and biochemistry. Science 1985, 228:799-809.
69. Pichler B.J., Judenhofer M.S., Catana C., Walton J.H., Kneilling M., Nutt R.E., Siegel S.B., Claussen C.D., Cherry S.R. Performance test of an LSO-APD detector in a 7-T MRI scanner for simultaneous PET/MRI. J. Nucl. Med. 2006, 47:639-647.
70. Pichler B.J., Kolb A., Nägele T., Schlemmer H.P. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J. Nucl. Med. 2010, 51:333-336.
71. Pien H.H., Fischman A.J., Thrall J.H., Sorensen A.G. Using imaging biomarkers to accelerate drug development and clinical trials. Drug Discov. Today 2005, 10:259-266.
72. Pike V.W. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol. Sci. 2009, 30:431-440.
73. Ravina B., Eidelberg D., Ahlskog J.E., Albin R.L., Brooks D.J., Carbon M., Dhawan V., Feigin A., Fahn S., Guttman M., Gwinn-Hardy K., McFarland H., Innis R., Katz R.G., Kieburtz K., Kish S.J., Lange N., Langston J.W., Marek K., Morin L., Moy C., Murphy D., Oertel W.H., Oliver G., Palesch Y., Powers W., Seibyl J., Sethi K.D., Shults C.W., Sheehy P., Stoessl A.J., Holloway R. The role of radiotracer imaging in Parkinson disease. Neurology 2005, 64:208-215.
74. Rebois R.V., Allen B.G., Hébert T.E. The targetable G protein proteome: where is the next generation of drug targets?. Drug Discov. Today 2004, 3:104-111.
75. Rees G., Howseman A., Josephs O., Frith C.D., Friston K.J., Frackowiak R.S.J., Turner R. Characterizing the relationship between BOLD contrast and regional cerebral blood flow measurements by varying the stimulus presentation rate. NeuroImage 1997, 6:270-278.
76. Reynolds F., Kelly K.A. Techniques for molecular imaging probe design. Mol. Imaging. 2011, 10:407-419.
77. Riad M., Watkins K.C., Doucet E., Hamon M., Descarries L. Agonist-induced internalization of serotonin-1A receptors in the dorsal raphe nucleus (autoreceptors) but not hippocampus (heteroreceptors). J. Neurosci. 2001, 21:8378-8386.
78. Riad M., Zimmer L., Rbah L., Watkins K.C., Hamon M., Descarries L. Acute treatment with the antidepressant fluoxetine internalizes 5-HT1A autoreceptors and reduces the in vivo binding of the PET radioligand [18F]MPPF in the nucleus raphe dorsalis of rat. J. Neurosci. 2004, 24:5420-5426.
79. Sawamoto N., Piccini P., Hotton G., Pavese N., Thielemans K., Brooks D.J. Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain 2008, 131:1294-1302.
80. Scarf A.M., Kassiou M. The translocator protein. J. Nucl. Med. 2011, 52:677-680.
81. Schreiber G., Avissar S. Regulators of G-protein-coupled receptor-G-protein coupling: antidepressants mechanism of action. Expert. Rev. Neurother. 2007, 7:75-84.
82. Schumacher J.M., Ellias S.A., Palmer E.P., Kott H.S., Dinsmore J., Dempsey P.K., Fischman A.J., Thomas C., Feldman R.G., Kassissieh S., Raineri R., Manhart C., Penney D., Fink J.S., Isacson O. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 2000, 54:1042-1050.
83. Schweitzer P.J., Fallon B.A., Mann J.J., Kumar J.S. PET tracers for the peripheral benzodiazepine receptor and uses thereof. Drug Discov. Today 2010, 21-22:933-942.
84. Schwochau K. Technetium radiopharmaceuticals-fundamentals, synthesis, structure, and development. Angew. Chem. Int. Ed. 1994, 33:2258-2267.
85. Seeman P., Guan H.C., Niznik H.B. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain. Synapse 1989, 3:96-97.
86. Shih Y.Y., Wey H.Y., De La Garza B.H., Duong T.Q. Striatal and cortical BOLD, blood flow, blood volume, oxygen consumption, and glucose consumption changes in noxious forepaw electrical stimulation. J. Cereb. Blood Flow Metab. 2011, 31:832-841.
87. Sibon I., Benkelfat C., Gravel P., Aznavour N., Costes N., Mzengeza S., Booij L., Baker G., Soucy J.P., Zimmer L., Descarries L. Decreased [18F]MPPF binding potential in the dorsal raphe nucleus after a single oral dose of fluoxetine: a positron-emission tomography study in healthy volunteers. Biol. Psychiatry 2008, 63:1135-1140.
88. Sokoloff L., Reivich M., Kennedy C., Des Rosiers M.H., Patlak C.S., Pettigrew K.D., Sakurada O., Shinohara M. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem. 1977, 28:897-916.
89. Strauss L.G., Conti P.S. The applications of PET in clinical oncology. J. Nucl. Med. 1991, 32:623-648.
90. Thathiah A., De Strooper B. The role of G protein-coupled receptors in the pathology of Alzheimer's disease. Nat. Rev. Neurosci. 2011, 12:73-87.
91. Thompson J.L., Urban N., Abi-Dargham A. How have developments in molecular imaging techniques furthered schizophrenia research?. Imaging Med. 2009, 1:135-153.
92. Tsukada H., Ohba H., Nishiyama S., Kakiuchi T. Differential effects of stress on [11C]raclopride and [11C]MNPA binding to striatal D[U+2082]/D[U+2083] dopamine receptors: a PET study in conscious monkeys. Synapse 2011, 65:84-89.
93. Udo de Haes J.I., Bosker F.J., Van Waarde A., Pruim J., Willemsen A.T., Vaalburg W., Den Boer J.A. 5-HT(1A) receptor imaging in the human brain: effect of tryptophan depletion and infusion on [(18)F]MPPF binding. Synapse 2002, 46:108-115.
94. van Gool A.J., Henry B., Sprengers E.D. From biomarker strategies to biomarker activities and back. Drug Discov. Today 2010, 15:121-126.
95. Venneti S., Lopresti B.J., Wiley C.A. The peripheral benzodiazepine receptor (translocator protein 18kDa) in microglia: from pathology to imaging. Prog. Neurobiol. 2006, 80:308-322.
96. Verbruggen A., Coenen H.H., Deverre R., Guilloteau D., Langstrom B., Salvadori P.A., Halldin C. Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:2144-2151.
97. Volkow N.D., Wang G.J., Fowler J.S., Tomasi D., Telang F. Addiction: beyond dopamine reward circuitry. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:15037-15042.
98. Wagner C.C., Langer O. Approaches using molecular imaging technology-use of PET in clinical microdose studies. Adv. Drug Deliv. Rev. 2011, 63:539-546.
99. Wester H.J., Herz M., Weber W., Heiss P., Senekowitsch-Schmidtke R., Schwaiger M., Stöcklin G. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-l-tyrosine for tumor imaging. J. Nucl. Med. 1999, 40:205-212.
100. Willeit M., Ginovart N., Graff A., Rusjan P., Vitcu I., Houle S., Seeman P., Wilson A.A., Kapur S. First human evidence of d-amphetamine induced displacement of a D2/3 agonist radioligand: a [11C]-(+)-PHNO positron emission tomography study. Neuropsychopharmacology 2008, 33:279-289.
101. Wimo A., Winblad B., Aguero-Torres H., von Strauss E. The magnitude of dementia occurrence in the world. Alzheimer Dis. Assoc. Disord. 2003, 17:63-67.
102. Zimmer, L., Descarries, L., in press. Internalization of serotonin 5-HT1a autoreceptors as an imaging biomarker of antidepressant response. WIREs Memb. Transp. Signal.
103. Zimmer L., Riad M., Rbah L., Belkacem-Kahlouli A., Le Bars D., Renaud B., Descarries L. Toward brain imaging of serotonin 5-HT1A autoreceptor internalization. NeuroImage 2004, 22:1421-1426.